Germline Testing Remains Low Among Patients With Upper Tract Urothelial Carcinoma
A nationwide claims-based analysis found that fewer than 5% of patients with newly diagnosed upper tract urothelial carcinoma underwent germline genetic testing, with little change in testing rates over an 8-year period. Testing remains uncommon even among patients meeting established criteria for genetic evaluation, including those diagnosed before age 50 years. The findings were reported by Korn et al in JCO Oncology Practice.
Upper tract urothelial carcinoma is the third most common malignancy associated with Lynch syndrome. Although clinical guidelines recommend genetic evaluation for patients with upper tract urothelial carcinoma, including tumor-based screening and referral for germline testing when indicated, population-level data on testing utilization have been limited.
Study Details
Investigators conducted a retrospective analysis using the MarketScan Commercial Claims and Encounters Database to identify patients with newly diagnosed upper tract urothelial carcinoma between January 2015 and June 2023. The database includes commercially insured patients in the United States but excludes Medicare and Medicaid beneficiaries.
The primary outcome was receipt of germline testing after upper tract urothelial carcinoma diagnosis, identified through claims for hereditary cancer genetic testing. Investigators examined testing rates across three periods (2015–2017, 2018–2019, and 2020–2023) and used univariable and multivariable logistic regression to identify factors associated with testing.
The study included 4,783 patients, with a median age at diagnosis of 58 years (interquartile range = 51–62 years). Of these, 1,018 (21.3%) were diagnosed before age 50 years, 2,664 (55.7%) were male, and 630 (13.2%) had a history of a Lynch-spectrum malignancy, defined as colorectal, endometrial, ovarian, or prostate cancer.
Key Results
Overall, 216 patients (4.5%) underwent germline testing following upper tract urothelial carcinoma diagnosis. Testing rates were 4.1% in 2015 to 2017, 5.5% in 2018 to 2019, and 4.4% in 2020 to 2023, with no statistically significant change over time (P = .15).
Patients with a prior Lynch-spectrum malignancy were more likely to undergo testing than those without such a history (9.7% vs 3.7%; P < .001). In multivariable analysis, prior Lynch-spectrum cancer was the strongest independent factor associated with testing (odds ratio [OR] = 3.00, 95% confidence interval [CI] = 2.14–4.22). Male sex was also associated with increased odds of testing (OR = 1.37, 95% CI = 1.01–1.86).
Geographic variation was observed, with testing rates ranging from 2.6% in the Northeast to 6.3% in the West. Compared with patients in the South, those in the Northeast had significantly lower odds of testing after multivariable adjustment (OR = 0.54, 95% CI = 0.34–0.85).
Among the 1,018 patients diagnosed before age 50 years, an established criterion for genetic evaluation, only 57 (5.6%) underwent testing. Among the 122 younger patients with a prior Lynch-spectrum malignancy, just 9 (7.4%) received germline testing.
Of the 216 patients who underwent germline testing, 8 (3.7%) subsequently had a Lynch syndrome diagnosis documented in claims data.
The investigators concluded: “Germline testing in [upper tract urothelial carcinoma] is performed in fewer than 1 in 20 patients and remains low even in patients meeting established clinical criteria for evaluation. Structural integration of germline evaluation into upper tract urothelial carcinoma care pathways is needed.”
Nirmish Singla, MD, MSCS, FACS, of the Department of Urology, The Brady Urological Institute at Johns Hopkins, Johns Hopkins School of Medicine, Baltimore; the Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore; Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore; and the Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, is the corresponding author for the JCO Oncology Practice article.
DISCLOSURE: For full disclosures of the study authors, visit ascopubs.org.